CD30 CAR T-cells Post AutoHSCT for Poor-risk Hodgkin Lymphoma (NCT06617286)

🧪 Interventions in This Study

• CD30 CAR T-cell (BIOLOGICAL)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Age between ≥ 6 and ≤ 29.99 years at the time of consent.
2. Lansky OR Karnofsky score of ≥ 60% (see Appendix VI)
3. Disease Status: Confirmed diagnosis of CD30+ classical Hodgkin Lymphoma and meets eligibility to undergo ASCT. Must meet one of the following: Induction failure Progressive disease Disease relapse (1st, 2nd or 3rd)
4. Confirmatory re-biopsy of relapse/refractory/persistent CD30+ cHL prior to study entry.
5. Risk Factors: Patient must meet 2 or more of the established risk factors: Performance score (Karnofsky/Lansky) \<;90% Time from diagnosis to first relapse of \<1 year Extra nodal involvement at the time of relapse/progression High baseline metabolic tumor volume (MTV, \>60mL) by 18F-fluorodeoxyglucose positron emission tomography (PET)/computed tomography (CT) Chemo resistant disease (Deauville 4-5) after the first re-induction

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

• New York Medical College — Valhalla, New York

📞 Contact the Study Coordinator

Phone: (914) 594-2150

Email: mitchell_cairo@nymc.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
• 💵 Compensation indicated: About 21-42 day after the autologous stem cell infusion, patients will receive their autologous CD30+ CAR T-cell infusion, if they meet subsequent pre CD30+ CAR T-cell eligibility criteria.

More studies in Classical Hodgkin Lymphoma

• Fitness-adapted, Pembrolizumab-based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above — New Brunswick, New Jersey
• Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma — Toronto, Ontario
• Itacitinib + Everolimus in Hodgkin Lymphoma — Philadelphia, Pennsylvania
• Ibrutinib and Nivolumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma — Atlanta, Georgia
• Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy — Duarte, California

Explore by condition: All Classical Hodgkin Lymphoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.